Skip to main content

Advertisement

Table 2 Mean (95% confidence interval) efficacy differences between treatments over 12 weeks

From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

  Etoricoxib vs placebo Naproxen vs placebo Etoricoxib vs naproxen
Primary endpoints    
Patient global assessment of disease activity (100 mmVAS) ‡ -9.93* (-12.96, -10.0* (-13.7, 0.09 (-3.61, 3.79)
  -6.90) -6.32)  
Investigator global assessment of disease activity (0–4 scale) ‡ -0.43* (-0.55, -0.51* (-0.66, 0.08 (-0.08, 0.24)
  -0.30) -0.35)  
Tender joint count (total 68 joints) ‡ -3.42* (-4.89, -3.16* (-4.96, -0.26 (-2.05, 1.54)
  -1.94) -1.36)  
Swollen joint count (total 66 joints) ‡ -1.43† (-2.42, -1.39† (-2.60, -0.03 (-1.24, 1.17)
  -0.44) -0.19)  
Secondary endpoints    
Patient global assessment of pain (100 mm VAS) ‡ -9.62* (-12.73, -10.46* (-14.25, 0.84 (-2.96, 4.63)
  -6.51) -6.66)  
Health Assessment Questionnaire disability (0–3 scale) ‡ -0.20* (-0.28, -0.29* (-0.38, 0.08 (0.00, 0.17)
  -0.13) -0.20)  
Serum C-reactive protein (ratio between treatments) 1.11† (1.00, 1.23) 0.99 (0.87, 1.13) 1.12 (0.99, 1.27)
ACR20 responder criteria (%) 17.83* (10.55, 25.12) 16.68* (7.80, 25.57) 1.15 (-7.74, 10.03)
Discontinuation due to lack of efficacy (%) -12.75* (-18.42, -14.71* (-21.06, 1.97 (-3.67, 7.61)
  -7.07) -8.37)  
  1. Note: Negative values indicate improvement except for ACR20 responder criteria and serum C-reactive protein. 
  2. * The difference vs placebo was significant (p<0.001). † The difference vs placebo was significant (p<0.05). ‡ For these measures, the difference shown is for the least squares mean of the time-weighted average change from baseline over 12 weeks. ACR20 responder criteria and Discontinuations due to lack of efficacy are shown as differences in frequency over the 12-week period. Serum C-reactive protein was calculated as a ratio between treatments over the 12-week treatment period.